Trials / Completed
CompletedNCT02915159
A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with Sjögren's Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Abatacept | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-12-06
- Primary completion
- 2018-08-07
- Completion
- 2019-07-23
- First posted
- 2016-09-26
- Last updated
- 2020-08-10
- Results posted
- 2020-01-02
Locations
71 sites across 13 countries: United States, Argentina, Australia, Brazil, Czechia, France, Germany, Italy, Japan, Mexico, Puerto Rico, South Korea, Sweden
Source: ClinicalTrials.gov record NCT02915159. Inclusion in this directory is not an endorsement.